Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

NCT05997017 is registered in ClinicalTrials.gov with Aadi Bioscience, Inc. as lead sponsor.

NCT NCT05997017
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05997017 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-center Open-label Trial of Nab-Sirolimus in Combination With Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Lead sponsor
Aadi Bioscience, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
December 28, 2023
Completion date
June 30, 2027
Enrollment
29 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, endometrial cancer, endometrioid endometrial cancer, endometrioid tumor, recurrent endometrial carcinoma, tumor